DOI: http://dx.doi.org/10.18203/issn.2454-5929.ijohns20171185

Montelukast: a better alternative than antihistaminics in allergic rhinitis

Gurpreet Kaur, Rachna Dhingra, Manjinder Singh, Manpreet Kaur

Abstract


Background: Allergic rhinitis is associated with sleep disturbances, daytime somnolence, and fatigue. Hence, present study was undertaken to evaluate and compare the nocturnal symptoms such difficulty in going to sleep, night time awakening and nasal congestion/obstruction on awakening among allergic rhinitis patients after administration of montelukast, chlorpheniramine meleate, levocetrizine, desloratidine and fexofenadine and to find out anti-allergic drug with maximum improvement in total symptom complex score.

Methods: The present study comprised of 125 patients suffering from allergic rhinitis on the basis of characteristic history, corroborative physical findings and blood eosinophilia. Night times symptoms including difficulty in going to sleep, night time awakenings and nasal congestion on awakening were evaluated after patients were given oral treatment with chlorpheniramine maleate, levocetrizine, fexofenadine, desloratadine and montelukast for a period of 6 weeks in different 5 groups and the result interpreted on the basis of symptoms relieved. Symptoms were recorded on day 1, 2 weeks, 4 weeks and 6 weeks of treatment and analysed. All the patients were randomly divided into five groups of 25 each. The results were tabulated and analyzed by chi-square, Kruskal-Wallis test.  

Results: The present study found that levocetirizine provided immediate effect at 2 weeks which is significantly better than other drugs. But at 6 weeks, montelukast is best among the drugs which were compared; followed by levocetrizine, fexofenadine, and desloratadine and chlorpheniramine maleate.  Montelukast was found to be a better drug as it has no significant side effects. Desloratadine group had dryness of mouth. Chlorpheniramine maleate has maximum side effects. 6 patients who took chlorpheniramine maleate complained of sedation, 1 patient complain of psychomotor disturbance.

Conclusions: The present study concludes that in terms of clinical efficacy, safety/tolerability and improvement in night time symptom scores at six weeks therapy in allergic rhinitis, montelukast is the better drug.


Keywords


Allergic rhinitis, Antihistamines, Montelukast, Levocetrizine, Desloratidine, Fexofenadine

Full Text:

PDF

References


Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician. 2010;81(12):1440-6.

Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol. 2004;114(5):146-53.

Kaur G, Phillips CL, Wong K, McLachlan AJ, Saini B. Timing of administration: For commonly-prescribed medicines in Australia. Pharmaceutics. 2016;8(2):13.

Lagos JA, Marshall GD. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag. 2007;3(2):327-32.

Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887-901.

Sausen VO, Marks KE, Sausen KP, Self TH. Management of allergic rhinitis. J Pediatr Pharmacol Ther. 2005;10(3):159-73.

Gupta V, Matreja PS. Efficacy of montelukast and levocetrizine as treatment for allergic rhinitis. J Aller Ther. 2010;1:103.

Okubo K, Baba K. Therapeutic effect of montelukast, a cysteinyl leukotriene receptor 1 antagonist. Allergol Int. 2008;57(3):247-55.

Axelrod D, Bielory L. Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy. 2008;1:19-29.

Spangler DL, Brunton S. Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med J. 2006;99(6):593-9.

Geha RS, Meltzer EO. Desloratadine: A new nonsedating oral antihistamine. J Allergy Clin Immunol. 2001;107(4):751-62.

Ciebiada M, Ciebada MG, Kmiecik T, DuBuske LM, Gorski P. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or Desloratadine. J Investig Allergol Clin Immunol. 2008;18(5):343-9.